_sreen.jpg)
Mistelihoidon
aineosat ja vaikutus
Immuunimodulatooriset vaikutukset
In vivo -tutkimukset soluviljelmissä ja eläinmalleilla
Ma L, Phalke S, Stevigny C, Souard F, Vermijlen D: Mistletoe-extract drugs stimulate anti-cancer Vγ9Vδ2 T cells. Cells 2020, 9 (6), 1560. 15 pp. DOI: 10.3390/cells9061560.
Bhutia SK, Panda PK, Sinha N, Praharaj PP, Bhol CS, Panigrahi DP, Mahapatra KK, Saha S, Patra S, Mishra SR, Behera BP, Patil S, Maiti TK. Plant lectins in cancer therapeutics: Targeting apoptosis and autophagy-dependent cell death. Pharmacological Research 2019;144: 8-18. DOI: 10.1016/j.phrs.2019.04.001.
Oei SL, Thronicke A and Schad F. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies. Evid Based Complement Alternat Med. 2019;2019:5893017
Huber R, Gründemann C. Die Wirkungen der Mistelsubstanz auf das Immunsystem und mögliche therapeutische Implikationen. Der Merkurstab. Zeitschrift für Anthroposophische Medizin 2018;71(4):265-268. DOI: https://doi.org/10.14271/DMS-20964-DE
Steinborn C, Klemd A M, Sanchez-Campillo A S, Rieger S, Scheffen M, Sauer B, Garcia-Kaufer M, Urech K, Follo M, Ucker A, Kienle G S, Huber R and Grundemann C. Viscum album neutralizes tumor-induced immunosuppression in a human in vitro cell model. PLoS One, 2017;12:e0181553. DOI: 10.1371/journal.pone.0181553
Gamerith G, Amann A, Schenk B, Auer T, Lentzen H, Mügge DO, Cima KM, Löffler-Ragg J, Hilbe W, Zwierzina H. Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells. Oncology Letters 2017;14(5):5563-5568. DOI: 10.3892/ol.2017.686
Saha C, Das M, Stephen-Victor E, Friboulet A, Bayry J and Kaveri S V. Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4(+) T Cell Responses. Molecules, 2016;21. DOI: 10.3390/molecules21070912
Rieger S. Immunologische Effekte verschiedener Mistelextrakte in Wechselwirkung mit humanen Tumorzellüberständen – ein Modell mit Dendritischen Zellen. Dissertation, Universität Freiburg, 2015.
Kim J-J, Hwang Y-H, Kang K-Y et al. Enhanced dendritic cell maturation by the B-chain of Korean mistletoe lectin (KML-B), a novel TLR4 agonist. International Immunopharmacology 2014;21(2):309–319. 2014.
Podlech OP, Harter PN, Mittelbronn M, Pöschel S and Naumann U. Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med. 2012;2012:501796. doi: 10.1155/2012/501796. Epub 2012 Oct 22.
Huber R, Lüdtke H, Wieber J and Beckmann C. Safety and effects of two mistletoe preparations on production of Interleukin-6 and other immune parameters - a placebo controlled clinical trial in healthy subjects. BMC Complementary and Alternative Medicine, vol. 11, no. 116, 2011. DOI: doi.org/10.1186/1472-6882-11-116
Büssing, A . Immune modulation using mistletoe (Viscum album L.) extracts iscador. Arzneimittelforschung. 2011;56(06):508-515. doi:10.1055/s-0031-1296818
Google Scholar | Crossref
Hajto T, Fodor K, Perjesi P and Nemeth P. Difficulties and perspectives of
immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine. Evid Based Complement Alternat Med, 2011;2011:298972. DOI: 10.1093/ecam/nep191
Hegde P, Maddur MS, Friboulet A, Bayry J and Kaveri SV. Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. PLoS ONE 2011;6(10), Article ID e26312. 2011.
Braedel-Ruoff S. Immunomodulatory effects of Viscum album extracts on natural killer cells: review of clinical trials. Forsch Komplementmed, 2010;17:63-73. DOI: 10.1159/000288702
Elluru SR, JP Duong van Huyen, S Delignat, MD Kazatchkine, A Friboulet, SV Kaveri and J Bayry: Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer. 2008; 8: 161.
Elluru S, JPD Huyen van, B Wootla, S Delignat, F Prost, VS Negi and SV Kaveri: Tumor regressive effects of Viscum album preparations – Exploration of immunomodulatory mechanisms. Medicina. 2007; 67: 85-89.
Schink M, Tröger W, Dabidian A, Goyert A, Scheuerecker H, Meyer J, Fischer I U and Glaser F. Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. a randomized phase III trial. Forsch Komplementmed, 2007;14:9-17. DOI: 10.1159/000098135
Elluru S, JP Duong Van Huyen, S Delignat, F Prost, J Bayry, MD Kazatchkine and SV Kaveri: Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung. 2006; 56: 461-466.
Schink M, Tröger W, Goyert A, Scheuerecker H, Selbmann H K and Glaser F. [Correlation of NK cell activity against autologous tumour cells and K562 cells with the clinical outcome during therapy with mistletoe extracts]. Forsch Komplementmed, 2006;13:147-155. DOI: 10.1159/000092624
Huber R, Classen K, Werner M and Klein R. In vitro immunoreactivity towards lectin-rich or viscotoxin-rich mistletoe (Viscum album L.) extracts Iscador applied to healthy individuals. Arzneimittelforschung, 2006;56:447-456. DOI: 10.1055/s-0031-1296811
Heinzerling L, von Baehr V, Liebenthal C, von Baehr R and Volk H D. Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, ex vivo, and in vivo. J Clin Immunol, 2006;26:347-359. DOI: 10.1007/s10875-006-9023-5
Huber R, Rostock M, Goedl R, Ludtke R, Urech K, Buck S and Klein R. Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects. Eur J Med Res, 2005;10:411-418
Klein R, Franz M, Wacker R, Classen K, Scheer R, von Laue HB, Stoeva S and Voelter W. Demonstration of antibodies to the chitin-binding mistletoe lectin (cbML) in tumor patients before and during therapy with an aqueous mistletoe extract. Eur J Med Res 2004;9:316-322.
Büssing A, M Bischof, W Hatzmann, F Bartsch, D Soto-Vera, EM Fronk, M Gmeindl and GM Stein: Prevention of surgery-induced suppression of granulocyte function by intravenous application of a fermented extract from Viscum album L. in breast cancer patients. Anticancer Res. 2005; 25: 4753-4757.
Klein R, Classen K, Berg PA, Lüdtke R, Werner M and Huber R. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals. European Journal of Medical Research, 2002;7(4):155–163, 2002.
Enesel MB, Acalovschi I, Grosu V et al. Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Research 2005;25(6):4583–4590.
Wong C K, Zhang J, Ip W K and Lam C W. Intracellular signal transduction in eosinophils and its clinical significance. Immunopharmacol Immunotoxicol, 2002;24:165-186. DOI: 10.1081/IPH-120003748
Tabiasco J, Pont F, Fournie J J and Vercellone A. Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. Eur J Biochem, 2002;269:2591-2600. DOI: 10.1046/j.1432-1033.2002.02932.x
Schink M and M Borowsky (2001). Zytotoxische Effekte von Mistellektinen und einem Mistelpräparat auf menschliche natürliche Killerzellen in vitro. 163-176. In: Scheer R., Bauer R., Becker H., Berg P. A., Fintelmann V. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik: 163-176. KVC Verlag Essen 2001, ISBN 3-933351-22-7
Siegle I, Fritz P, McClellan M, Gutzeit S and Murdter TE. Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells. Anticancer Res 2001;21:2687-2691.
Stein GM, U Edlund, G Schaller, U Pflüller, A Büssing and M Schietzel (2001). Polysaccharide und Viscotoxine – Immunologische Wirkungen und Interaktionen. In: Scheer R., Bauer R., Becker H., Berg P. A., Fintelmann V. (Hrsg.): Die Mistel in der Tumortherapie, Grundlagenforschung und Klinik:.145-161. KVC Verlag Essen 2001, ISBN 3-933351-22-7.
Yoon TJ, Yoo YC, Kang TB, Kim I, Kim J-B, Park, Y-H, Yoo Y-C and Yee S-T. Cellular and humoral adjuvant activity of lectins isolated from Korean mistletoe (Viscum album colaratum). International Immunopharmacology 2001; 1(5):881–889. 2001.
Elsasser-Beile U, Voss M, Schuhle R and Wetterauer U. Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal, 2000;14:255-259. DOI: 10.1002/1098-2825(20001212)14:6<255::aid-jcla1>3.0.co;2-j
Huber, R, Barth, H, Schmitt-Gräff, A, Klein, R. Hypereosinophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma. J Altern Complement Med. 2000;6(4):305-310. doi:10.1089/10755530050120664 Google Scholar | Crossref | Medline
Antony S, 226. Antony S, Kuttan R and Kuttan G. Role of natural killer cells in
Iscador mediated inhibition of metastasis by adoptive immunotherapy. Immunol Invest, 2000;29:219-231
Büssing A, Rosenberger A, Stumpf C and Schietzel M. Development of lymphocyte subsets in tumor patients after subcutaneous administration of mistletoe extracts. Forsch Komplementarmed 1999;6(4):196–204.
Kuttan R and Kuttan G. Inhibition of lung metastasis by adoptive immunotherapy using Iscador. Immunol Invest, 1999;28:1-8
Büssing A and M Schietzel: Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999; 19: 23-28.
Büssing A, W Vervecken, M Wagner, B Wagner, U Pfüller and M Schietzel: Expression of mitochondrial Apo2.7 molecules and caspase-3 activation in human lymphocytes treated with the ribosome-inhibiting mistletoe lectins and the cell membrane permeabilizing viscotoxins. Cytometry. 1999; 37: 133-139.
Antony S, Kuttan R and Kuttan G. Effect of viscum album in the inhibition of lung metastasis in mice induced by B16F10 melanoma cells. J Exp Clin Cancer Res, 1997;16:159-162
Stein GM and Berg PA. Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs 1997;8 Suppl 1:39-42.
Stein GM, Stettin A, Schultze J and Berg PA. Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts. Anticancer Drugs 1997;8 Suppl 1:57-59.
Büssing A, K Suzart, J Bergmann, U Pfüller, M Schietzel and K Schweizer: Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett. 1996; 99: 59-72.
Büssing, A. Induction of apoptosis by the mistletoe lectins: A review on the mechanisms of cytotoxicity mediated by Viscum album L. Apoptosis (1996) 1: 25.
Büssing A, Regnery A and Schweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett, 1995;94:199-205. DOI: 10.1016/0304-3835(95)03850-v
Büssing A, Azhari T, Ostendorp H, Lehnert A and Schweizer K. Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J Cancer, 1994;30A:1836-1841. DOI: 10.1016/0959-8049(94)00299-k
Kovacs E, Hajto T and Hostanska K. Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador). Eur J Cancer, 1991;27:1672-1676
Beuth J, Ko HL, Gabius H, Burrichter H, Oette K and Pulverer G. Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. The Clinical Investigator 1992;70(8):658–661.
Hajtó T, Hostanska K, Frei K, Rordorf C and Gabius HJ. Increased secretion of tumor necrosis factor α, interleukin 1, and interleukin 6 by human mononuclear cells exposed to β-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Research 1990;50(11):3322-3326.
Ribereau-Gayon G, Jung ML, Baudino S, Salle G and Beck JP. Effects of mistletoe (Viscum album L.) extracts on cultured tumor cells. Experientia 1986;42:594-599.
Hajto T. Immunomodulatory effects of iscador: a Viscum album preparation. Oncology 1986; 43(1):51–65. DOI:10.1159/000226420.